Opinion|Videos|October 11, 2024
Integration of GPRC5D-Targeted Therapies in RRMM Treatment
Panelists discuss how GPRC5D-targeted bispecifics are likely to be incorporated earlier in treatment sequencing for multiple myeloma in the future, while considering factors such as optimal timing, potential combinations with other therapies, sequencing strategies, and possible drug interactions when integrating these treatments into the overall management of relapsed/refractory multiple myeloma patients.
Advertisement
Episodes in this series
- Where in treatment sequencing do you foresee future GPRC5D-targeted bispecifcs being incorporated?
- How have you integrated GPRC5D-targeted therapies into the overall treatment landscape for heavily pre-treated RRMM patients?
- What considerations should be made when integrating GPRC5D-targeted treatments alongside other therapies in terms of sequencing, combination approaches, and potential drug-drug interactions
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5